Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer
Li, N., Bu, H., Liu, J., Zhu, J., Zhou, Q., Wang, L., Yin, R., Wu, X., Yao, S., Gu, K., Zhang, H., Li, G., Pan, H., Wu, Q., An, R., Yang, X., Zhu, Y., Wan, X., Duan, W., Xiong, J., Wang, Y., Wang, Q.,Volume:
159
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2020.05.229
Date:
October, 2020
File:
PDF, 34 KB
2020